Mylan Stock Dives On $30 Million Settlement In EpiPen Scandal

Mylan plans to pay $30 million to settle a Securities and Exchange Commission lawsuit that alleges the pharmaceutical company failed to disclose potential losses in the wake of an EpiPen scandal. The generic pharmaceutical company overcharged Medicaid by "hundreds of millions of dollars," and drew the scrutiny of the U.S. Department of Justice, the SEC said in a news release issued Friday.